Villars Sur Glane

Researchers are evaluating the effectiveness and safety of Ifinatamab Deruxtecan I-DXd compared to the treatment chosen by a physician for people with relapsed small cell lung cancer SCLC. This Phase 3 study aims to see if I-DXd can help participants live longer than current treatments, while also examining other effects such as patient-reported outcomes, immune response, and the drugs behavior in the body. Participants will be randomly assigned to one of two groups. One group will receive I-DXd as an intravenous infusion at a dose of 12 mgkg every 21 days until the disease worsens, unacceptable side effects occur, or other stopping reasons arise. The other group will receive one of the standard treatments chosen by their doctortopotecan, lurbinectedin, or amrubicinaccording to local approved dosing guidelines and until treatment discontinuation criteria are met. During the study, participants will be closely monitored with regular imaging and assessments to track tumor response, disease progression, and quality of life using questionnaires. Safety events and immune responses will also be recorded. Pharmacokinetic samples will be collected at specified times to understand how I-DXd behaves in the body. Participants may remain in the study for up to approximately 3.7 years, allowing for long-term evaluation of outcomes and safety.

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in adults with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression level of 50% or higher. This Phase 3 randomized, double-blind study focuses on patients with locally advanced or metastatic NSCLC to better understand first-line treatment options. Participants receive either Pumitamig or Pembrolizumab as the study drug, given at specified doses on certain days. The study uses a parallel design with two treatment groups to compare these therapies as first-line options. The study is planned to continue until October 2031, with treatment and follow-up periods extending up to approximately 5 years for overall survival assessments. During the study, participants will have regular assessments to monitor disease progression and response to treatment using criteria like RECIST v1.1. Researchers will evaluate progression-free survival, overall survival, objective response rates, duration of response, disease control rate, and symptom changes related to lung cancer over time. Safety and treatment effects will be closely monitored throughout the study duration.

Researchers are evaluating the impact of adding digital checkboxes to the electronic triage system in an emergency department to improve patient flow and reduce the total length of stay. This before-and-after observational study compares patient throughput during a pre-intervention phase from May 1st to July 31st, 2026, with a post-intervention phase during the same months in 2027 to minimize seasonal effects. The primary focus is on the total Emergency Department Length of Stay ED LOS. The intervention involves introducing digital anticipatory protocols at triage, which provide nurses with structured options for expected patient management based on acuity. During the pre-intervention phase, patients undergo the standard triage assessment using the Swiss Emergency Triage Scale, while the post-intervention phase adds the digital checkboxes. Patient disposition decisions are tracked using digital tags in electronic health records throughout both phases. Participants are patients aged 18 years and older who register at the emergency department admission desk during the study periods. Researchers monitor outcomes such as total ED length of stay, patients who leave without being seen, 30-day mortality, and transfers to intensive care units. The study observes participants through completion of the ED visit, up to a maximum of 72 hours, with some outcomes followed up to 30 days or 7 days post-visit. This allows assessment of patient flow improvements and safety over time.

Researchers are evaluating the efficacy and safety of Adagrasib alone and in combination with pembrolizumab for patients with advanced or metastatic non-small cell lung cancer NSCLC that has a KRAS G12C mutation. The study includes a Phase 2 portion that assesses these treatments in patients with various PD-L1 tumor proportion scores TPS and a Phase 3 portion that compares Adagrasib plus pembrolizumab to pembrolizumab alone in patients with higher PD-L1 TPS 50%. The goal is to understand how these treatments work as first-line therapy in this patient population. Treatment involves Adagrasib administered orally twice daily BID either alone or combined with pembrolizumab, which is given intravenously at 200 mg every three weeks. Phase 2 includes three cohorts based on PD-L1 status and treatment type, while Phase 3 randomly assigns patients to receive either the combination or pembrolizumab alone. Patients with unresectable or metastatic squamous or nonsquamous NSCLC are included, with specific brain metastases criteria for Phase 3 participants. Participants will be monitored over periods of up to 22 months in Phase 2 and 36 months in Phase 3. Assessments include measuring treatment efficacy, safety, pharmacokinetics, quality of life, and tumor response using RECIST 1.1 criteria. Regular evaluations involve imaging, clinical exams, and patient-reported outcomes. The study aims to provide detailed information on treatment tolerability and effectiveness during and after therapy.

Researchers are studying primary and acquired resistance mechanisms to standard treatments targeting BRAF V600E mutations in metastatic colorectal cancer. This observational study focuses on patients receiving combined therapy with BRAF inhibitor encorafenib, anti-EGFR antibody cetuximab, and chemotherapy. Resistance to this combination often develops, limiting treatment options, so the study aims to uncover genetic and non-genetic reasons behind this resistance to help develop better future therapies. Participants will receive standard-of-care treatment with encorafenib, cetuximab, and possibly chemotherapy. Before starting treatment and at the time of disease progression, researchers will collect tumor tissue, blood, and stool samples. These samples will be used to study molecular changes and the microbiome, and to create patient-derived organoids for laboratory testing. Blood samples will be collected regularly during treatment to analyze circulating tumor DNA over time. Throughout the study, participants will be followed longitudinally with sample collections before treatment and at progression, continuing for up to around 24 months. Researchers will measure molecular alterations linked to resistance, compare tissue and liquid biopsy findings, characterize gut microbiome changes, and track tumor DNA dynamics. The studys findings aim to improve understanding of resistance and support personalized treatment approaches for metastatic colorectal cancer.

This research aims to evaluate whether reinforcing the abdominal wall with a mesh during closure after open abdominal aortic aneurysm AAA repair can prevent incisional hernias IH. The study is retrospective and observational, focusing on patients who had this mesh reinforcement technique between 2019 and 2024. Researchers want to understand if mesh use reduces hernia rates and how often related postoperative complications occur compared to cases without mesh reported in the literature. The treatment studied is prophylactic retromuscular mesh reinforcement, where a mesh is placed behind the rectus abdominis muscles during abdominal closure to strengthen the wall and reduce hernia risk. This is done by carefully dissecting muscle layers and placing a self-gripping polyester or composite mesh extending beyond the midline without tension. The mesh is secured and the abdominal layers are sutured closed. The study looks at patients treated at one hospital over several years with this technique. Participants underwent clinical follow-ups and abdominal ultrasounds to detect incisional hernias. They also completed quality-of-life questionnaires including EQ-5D and PROMIS. The primary outcome measured is the rate of incisional hernias within a specific timeframe January to April 2025. Secondary outcomes include rates of complications such as fascial dehiscence, seromas, surgical site infections, hematomas, and operative time. The study relies on reviewing medical records and follow-up data from at least one year after surgery.

Researchers are investigating a new drug called ALE.F02 to see if it can help protect and preserve kidney function in people with antineutrophil cytoplasmic antibody ANCA associated vasculitis AAV, an autoimmune disease where the immune system attacks small blood vessels, often affecting the kidneys. The study aims to determine if ALE.F02 is safe, well tolerated, and effective when added to standard therapy for kidney inflammation caused by AAV. Participants will be assigned to one of four groups standard treatment plus ALE.F02 at low, high, or maximum doses, or standard treatment plus placebo infusions. The treatment phase lasts 24 weeks, during which participants receive 13 infusions of ALE.F02 or placebo alongside their usual therapy for AAV-related kidney inflammation. The study includes monitoring of physical health, blood and urine tests, and lung CT scans to assess vasculitis involvement. Throughout the study, participants will undergo physical exams, blood and urine sample collections to monitor kidney function, detect antibodies against the study drug, and measure biomarkers indicating disease activity. Lung scans are performed at the start and at Week 24 if lung involvement is detected. Researchers will evaluate safety and tolerability of ALE.F02 and measure changes in kidney function and protein levels over time. The study may continue up to one year to monitor outcomes and safety.

Researchers are evaluating treatments for patients with previously untreated follicular lymphoma who have a FLIPI score of 2 to 5. This phase III, randomized, open-label trial compares the combination of mosunetuzumab and lenalidomide with anti-CD20 monoclonal antibody plus chemotherapy. The study aims to assess the efficacy and safety of these treatments in managing this type of lymphoma. Participants enter a screening period lasting up to 6 weeks before randomization and treatment. Those randomized to the experimental arm receive mosunetuzumab with step-up dosing followed by lenalidomide over an induction phase of about 11 months, then a maintenance phase lasting up to 17 months, totaling around 30 months of treatment. The control arm includes different combinations of anti-CD20 antibodies with chemotherapy drugs CHOP or bendamustine over induction phases of about 5 months, followed by maintenance for up to 22 months, also totaling about 30 months. Patients are not allowed to switch from control to experimental treatments. Throughout the study, participants undergo regular follow-up visits for up to 7 years after the last patient is randomized. Follow-up includes assessments every 3 months for the first two years, then every 6 months for three years, and yearly thereafter. Researchers monitor progression-free survival, overall survival, response rates, adverse events, and other health measures. The total study duration is expected to be around 10 years from the start of enrollment to final follow-up.